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The Measurement of Human 
Chorionic Gonadotropin for Pregnancy Testing 
Carolyn S. Feldkamp, PhD * and Will iam H. Pfeffer, M D 
/Among many measurable hormones, human chorionic 
gonadotropin (FICG) is commonly used for pregnancy 
testing because it is very sensitive and relatively specific. 
Pregnancy can be identified shortly after implantation. 
Because some reagents cross-react with luteinizing 
hormone (LH), the sensitivity of urine tests has been 
adjusted to maintain specificity. Radioreceptor assay s on 
serum are more sensitive than urine tests but similarly 
lack specificity. The problems of LH cross-reactivity are 
eliminated by antisera specific for the beta subunit. 
Quantitation of HCG provides additional information 
useful in diagnosing ectopic pregnancy, providing a 
prognosis in threatened abortion, and following neo-
plasms. Considerations of cost, availability, accuracy, 
and sensitivity determine which test should be selected. 
T h e use of human chorionic gonadotropin (HCG) mea-
surements as a screening test to determine pregnancy is 
a sensitive issue in laboratory service. Both positive and 
negative results often have significant emotional impact 
on the patient. In addit ion, the laboratory and the cl ini-
cian are under constant scrutiny, since apparently false 
positive or false negative results soon become evident. A 
thorough understanding of the various test methods 
available and their limitations is required to use the 
service appropriately. Factors such as analytical sensitiv-
ity and specificity, turnaround t ime, personnel t ime, 
cost, and the clinical demand all must be considered in 
choosing the appropriate test. 
Endocrinology of Early Pregnancy 
It is essential to understandtheendocrinology and phys-
iology of early pregnancy in order to select pregnancy 
tests appropriately. Elevated serum hormones in women 
come from three sources: the corpus luteum, the pla-
centa, and the maternal pituitary gland. 
Corpus luteum 
In a typical human non-pregnant cycle, one oocyte— 
with its surrounding investment of zona pelucida, granu-
losa cells, basement membrane, and theca cells— 
establishes dominance over other ovarian steroid-
producing elements. In the days just before ovulation, 
this dominant foll icle secretes increasing amounts of 
estradiol so that the reproductive tract is receptive to 
sperm and also elicits a surge of luteinizing hormone 
(LH) f rom the pituitary gland. The LH surge initiates 
ovulat ion: maturation of the oocyte, release of the egg, 
and luteinization. The dominant foll icle, bereft of its 
oocyte and invaded by blood vessels, become the cor-
pus luteum. In theabsenceof " rescue" by trophoblastic 
gonadotropin and under the luteolytic influence of 
endometrial prostaglandin, the corpus luteum secretes 
estrogen and progesterone for 12-16 days only. If preg-
nancy does not occur, progesterone levels drop, the 
endometrial l ining sloughs, and menses ensues. 
The normally evanescent life of the corpus luteum is 
altered by ferti l ization and subsequent implantation of 
the cleaving zygote. When the zygote invades the 
endometr ium one week after ferti l ization, human cho-
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rionic gonadotropin (HCG) of embryonic origin enters 
the maternal circulation. In the corpus luteum HCG 
occupies LH-HCG receptors and stimulates the enzyme 
systems necessary for continued estrogen and proges-
terone product ion. Whether f rom a normal pregnancy, 
an embryonic blighted ovum, or an ectopic gestation, 
the HCG produced by the viable trophoblast permits the 
corpus luteum to cont inue to secrete estrogen and 
progesterone. 
At five to seven weeks after conception, trophoblastic 
secretion of estrogen and progesterone exceeds that of 
the corpus luteum. Estrogen and progesterone produc-
tion in the placenta increases until the third trimester. 
The waning function of the corpus luteum is marked bya 
fall in 17-OH progesterone (Fig. 1). 
Trophoblastic products 
One of the many polypeptide products of the t ropho-
blast is human placental lactogen (HPL). HPL is structur-
ally analogous to prolactin but functionally similar to 
growth hormone, directing maternal carbohydrate and 
fat metabolism to provide glucose and fatty acids to the 
fetus. HPL does not appear in maternal serum in analyti-
cally significant amounts until the fourth week after 
conception. 
The trophoblast also secretes several other pregnancy-
specific proteins. Some are thought to protect the 
embryo f rom immune rejection, whi le others such as 
alkaline phosphatase are isomers of common enzymes. 
Al though they are secreted in large amounts, the func-
tions of these pregnancy-specific proteins are unknown. 
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Fig.1 
First trimester serum levels of chor ionic gonadotrop in (HCG), estardiol 
(E2), estr io l (E3), progesterone (P), and 17-hydroxyprogesterone 
(17-OHP). 
When the corpus luteum dies, the placenta becomes the 
principal source of steroid hormones in pregnancy. Of 
these,estrioI is secreted in especially prodigiousamounts 
late in pregnancy. Although estriol is normally detected 
in l imited amounts in the non-pregnant woman as a 
metabolite of estradiol, it increases a thousandfold by 
the th i rd trimester. The fetal adrenal gland is essential to 
this increased product ion of estriol. During the first t r i -
mester, when this gland is absent or just forming, estriol 
levels are not elevated enough to be clinically useful. 
Maternal hormones 
Maternal pituitary gonadotropins are suppressed by 
estrogen and progesterone originating in the corpus 
luteum and placenta. The maternal thyroid and adrenal 
glands continue to funct ion at normal or minimally 
increased levels, whi le maternal prolactin increases sig-
nificantly. Various experiments indicate that increased 
prolactin is not essential to the survival of a pregnancy. 
Rather, elevated prolactin levels reflect increased estro-
gen stimulation of the pituitary gland. Estrogen also 
stimulates the liver to increase product ion of many 
proteins, including clott ing factors, l ipoprotein constit-
uents, and binding proteins for cortiocosteroids, thyrox-
ine, and testosterone/estrogen. 
Choice Oi' a Pregnancy Marker 
Because many hormones are either characteristically 
elevated or secreted only during pregnancy, measure-
ment of a particular substance depends on clinical and 
analytical considerations. Clinically, the ideal pregnancy 
hormone should appear only in pregnancy, change in a 
characteristic manner throughout pregnancy, and reflect 
the moment- to-moment status of the pregnancy. Ana-
lytically, the assay should be rapid, accurate, precise, and 
free f rom interference by cross-reacting substances. 
Estrogen and progesterone are not specific enough to 
identify early pregnancy, because their levels rise slowly 
in the first trimester and do not differ markedly from the 
non-pregnant state at that time (Fig. 1). 
In established pregnancies, the short half-lives of circu-
lating estrogen and progesterone allow sensitive moni-
tor ing of changes. I n the first trimester a dropping estra-
diol level augurs impending miscarriage, whereas in the 
third trimester estriol variations reflect feto-placental 
well-being. 
The measurement of prolactin and estrogen-stimulated 
liver proteins is subject to limitations similar to those of 
estrogen, since levels rise only gradually through the 
first trimester. In addit ion, several non-pregnant states 
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(exogenous hormones and pituitary adenoma) can cause 
specious elevations. 
The immunologically distinct polypeptide products of 
the trophoblast are excellent candidates for pregnancy 
testing. Placental lactogen is specific but not sensitive, 
since it is not measurable above background levels until 
the sixth week after the patient's first missed period. In 
some cases, the pregnancy-specific proteins have been 
noted to rise at the sametime as HCG. Al though it is not 
popular at the present t ime, the measurement of these 
substances might someday complement or supplant the 
determination of HCG for pregnancy testing. 
Of several endocrine markers for biochemical events 
during pregnancy, HCG has had the widest application 
for both detecting and monitor ing the course of preg-
nancy during the first two to three months of gestation. 
It has the desirable characteristic of originating exclu-
sively from trophoblastic tissue, except in the case of 
certain non-trophoblastic tumors (often of germ cell 
origin). In addit ion to its specificity for tissue of or igin, 
HCG rises exponentially during early pregnancy as a 
reflection of trophoblast function (Figs. 1,2). Finally, ana-
lytical methods with increased sensitivity and specificity 
make HCG an important clinical too l , as discussed 
below. 
Chorionic gonadotropin 
HCG is a glycoprotein hormone secreted by the tro-
phoblast and, subsequently, by the chorion and pla-
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Mean LH and HCG levels In early pregnancy and pregnancy test 
sensitivities. Shaded area shows pat ient- to-pat ient variations in the 
normal populat ion. 
centa. The hormone, which has a molecular weight of 
36,000-40,000 daltons, is composed of two non-covalently 
bound subunits designated alpha and beta. The alpha 
subunit is essentially identical to the alpha subunit o f the 
pituitary hormones LH, foll icle stimulating hormone 
(FSH), and thyroid stimulating hormone (TSH). Each of 
these is distinguished biologically and immunologically 
by the respective, unique beta subunit. Besides possess-
ing a common alpha subunit, LH and HCG exhibit exten-
sive homology in the beta subunit. The beta subunit of 
HCG possesses 30 additional amino acids at the carboxy I 
end, but this amino acid " t a i l " does not appear to affect 
its biological activity. Since both LH and HCG bind with 
equal affinity to identical receptors in vivo, they are 
equivalent in bioassays and ligand binding assays which 
use membrane receptors. This cross-reactivity is particu-
larly important in interpreting radioreceptor assays which 
use bovine corpus luteum. Antisera directed against the 
carboxyl terminus of the beta subunit may distinguish 
between hormones containing different beta subunits 
(LH and HCG) or in some cases between the free subunit 
and intact hormone. The development of these so-
called beta HCG antisera has made it possible to meas-
ure HCG specifically in the presence of physiological 
levels of LH. 
Normal serum levels of HCG for men and non-pregnant 
women are less than 10 m lU /m l . The least detectable 
dose for the radioimmunoassay (RIA) currently in use is 
3 m l U / m l . Thus, HCG is detectable by RIA in the non-
pregnant state as well as the preimplantation phase of 
pregnancy. Beginning shortly after implantation, approx-
imately eight days after presumed ovulation, HCG rises 
rapidly (Fig. 2). Braunstein, et al (1) reported mean serum 
HCG values during early pregnancy of 21.6 m lU /m l 
(10.3-33.0) at 3-3.5 weeks after the last menstrual period 
and of 353 m lU /m l (264-442) at 4-4.5 weeks. An exponen-
tial increase with a doubl ing t ime of 1.7-2.0 days was 
evident, reaching a peak of 100,000-200,000 m lU /m l at 
8-12 weeks after the last menstrual period. Thereafter, 
HCG plateaus over a wide range of normal values. For 
the duration of pregnancy, HCG levels remain above 
5,000 m lU /m l . 
The measurement of HCG levels for pregnancy testing 
has several limitations. Values may vary substantially 
f rom patient to patient for each day of gestation (Fig. 2, 
shaded area); thus, false negative results are possible. It 
is also diff icult to interpret whether a single value is 
"normal for gestational age." Moreover, since the bio-
logical half-life of intact HCG, which is the predominant 
species in serum, is approximately two days, it may be 
detectable up to four weeks after the pregnancy ends. 
209 
Feldkamp and Pfeffer 
Although the concentration of the hormone in urine 
parallels its concentration in serum, it is not a one-to-
one relationship. Typical graphs depicting analytical and 
clinical sensitivities (Fig. 2) usually reflect values deter-
mined on both urine and serum in different analytical 
ranges. Urine may also contain variable carbohydrate 
moieties as well as subunits and fragments, which are 
variably detectable by different assay methods. 
Laboratory Tests for Pregnancy 
Bioassay 
Essentially replaced by immunologic assays, the bioassay 
of HCG as a pregnancy test measured various parame-
ters such as sperm discharge, increased prostate weight, 
or ovarian corpora hemorrhagica in laboratory animals 
after they had been injected with a urine sample. While 
the assay was time consuming and imprecise, it detected 
pregnancy two to four weeks after the missed menses. 
Biological potency varied with clearance, fragmenta-
t ion, and desialation. 
Immunoassay 
Although results of the immunologic tests discussed 
below (Table 1) are expressed as units of biologic activity, 
measurements by immunoassay reflect hormone mass. 
Slide Test 
The UCG-slide test (Wampole Laboratories) is a rapid 
screening test of urine using the principle of latex agglut-
ination inhibi t ion (Fig. 3). Latex beads coated with HCG 
clump in the presence of rabbit anti-HCG. Sufficient 
free urinary HCG binds the specific antiserum and inhib-
its the c lumping of the latex beads. The reaction is per-
formed on a glass slide. In a negative test, c lumping will 
be visible in two minutes. 
This test is sensitive to2,000 m lU /m l urine and wil l relia-
bly detect pregnancy approximately 12 days after the 
missed period (30 days gestation). Al though LH reacts 
with the HCG antiserum, the test sensitivity is low 
enough that a normal LH surge should not interfere. 
Drawbacks to this test are that LH in menopausal urine 
wil l occasionally give a positive result. Also, some drugs, 
including phenothiazines and methadone metabolites, 
have been reported to cause false positive or false nega-
tive results. 
Tube Test 
Another urine pregnancy screening test is the UCG-
tube test (Wampole Laboratories), a hemagglutination 
inhibi t ion assay (Fig. 4). Red blood cells coated with 
HCG agglutinate to form a mat in the presence of antise-
rum to HCG. When urine containing HCG is added, 
agglutination is inhibited and the red cells settle to the 
bot tom of thetest tube in a button o rdoughnut pattern. 
The sample is compared to a contro l , and the test is 
complete in two hours. 
This test is sensitive to 500-1,500 m lU /m l of urine and is 
positive five to 12 days after the missed menstrual period 
if the patient has a follicular phase of consistent length. 
As is true with the slide test, LH cross-reacts with this 
antiserum. Given the increased sensitivity of this test, a 
false positive result in a perimenopausal woman is even 
more likely than with the slide test. Again, certain drugs 
may interfere. 
Slide and tube tests are subject to specific and non-
specific protein interferences, which usually give false 
positive results. In general, slide tests are more liable to 
interference by proteins. Caution is required to inter-
pret urine pregnancy tests in conditions (e.g., infections 
and kidney failure) with elevated levels of urine proteins. 
Radioreceptor Assays 
The radioreceptor assays (Wampole, Biocept-G) offer 
sensitivity adequate to detect HCG in serum 14 days after 
TABLE I 
Pregnancy Tests 
Analytical Clinical Performance 
Test Specimen Sensitivity Sensitivity Time 
UCG-slide test urine 2,000 m l U / m l 5-12 days after 2 min. 
missed period 
LICG-tube test urine 500-1,500 m l U / m l 5-12 days after 2 hr. 
missed period 
HCG, pregnancy screen serum 30 m l U / m l 7-14 days after 3 hr. 
(qualitative RIA) ovulat ion 
BHCG, quantitative serum 5 m l U / m l non-pregnant 41/2 h r . 
(RIA) 
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conception. In this assay, HCG and LH in serum compete 
with •'^si-labeled HCG for binding sites on bovine corpus 
luteum membranes. Radioactivity bound to receptor 
membrane is inversely proport ional to total hormone 
present (Fig. 5). As a pregnancy screening test, the cut-
off point for a "posi t ive" result, or its sensitivity, is set at 
200 m lU /m l . A normal LH surge does not result in false 
positive results. This test wil l detect some pregnancies by 
seven days of gestation and most pregnancies by the 
t ime of the expected menses. Serum proteins and drugs 
do not significantly interfere. 
HCG, Pregnancy Screen (RIA) 
At our institution the radioreceptor assay has been 
replaced as a serum pregnancy screening test by a qual-
itative radioimmunoassay. Enhanced specificity as well 
as sensitivity may be obtained by the use of antisera 
directed toward the unique carboxy-terminal end o f the 
beta subunit of HCG. These antisera bind intact HCG 
(the predominant circulating species) as well as free beta 
subunit but show very low cross-reactivity wi th pituitary 
hormones including LH. 
This HCG pregnancy screening test uses an antibody 
directed against the beta subunit of HCG (Leeco Diag-
nostics). HCG in patient serum competes with radio-
iodinated intact HCG for binding sites on the specific 
antibody (Fig. 6). Ant ibody-bound HCG is then precipi-
tated and counted in a gamma counter. Counts bound 
are inversely related to HCG concentration. A "posi t ive" 
result is correctly interpreted as "greater than 30 m lU /m l , " 
measured against a 30mlU/ml standard. This test may 
detect pregnancy as early as seven to ten days after 
presumed conception. 
k-HCG -F anthHCG 
HCG-coated latex 
beads 
urine 
HCG 
/HCG , 
HCG-0^CG 
clumping 
"negative' 
no clumping 
"positive" 
HCG-YI 
HCG 
HCG 
HCG 
Fig. 3 
UCC sl ide Test: Latex agglut inat ion inh ib i t ion assay. 
Results are considered "bo rde r l i ne " if they fall +5% 
around the cut-off point and represent analytical varia-
t ion. With a borderline result, the patient is either not 
pregnant or has a low concentration of HCG. These tests 
should be repeated after 24-48 hours for confirmation. 
Since this antibody cross-reacts with LH at a level of less 
than 5% (calculated on an IU basis), mid-cycle and 
menopausal LH concentrations should not give a false 
positive result. Unusual levels of LH and other sources of 
HCG must, of course, be considered in the clinical con-
text. Serum proteins and drugs are not significant 
problems. 
Interpretation of Results 
Although screening tests are commonly reported as 
"pos i t ive" or "negat ive," the only correct interpretation 
is "greater than" or "less t han " the stated cut-off value. 
Cut-off levels are set to maximize clinical reliability 
whi le min imiz ing the effect of known inter fer ing 
substances. 
Negative pregnancy tests 
A negative result f rom a pregnancy screening test does 
not mean "no t pregnant." Clearly, there is a concentra-
t ion below which HCG cannot be detected, varying 
f rom time of implantation (five to six days) to two to four 
weeks after the first missed menstrual period. No cur-
rently available pregnancy screening test wil l reliably 
detect pregnancy before implantation. 
Since HCG concentrations rise rapidly between six and 
36 days of gestational age, a negative result can easily 
become positive in 24-48 hours. 
Positive pregnancy tests 
Strictly speaking, none of the laboratory screening tests 
described above measure pregnancy as such. Rather, 
they use immunologic or biologic methods to measure 
@^HCG no HCG agglutination 
+ anti-HCG ^ "negative" 
(RB^ 
^ C G 
purine HCG 
no agglutination 
"positive" 
Fig. 4 
UCG Tube Test: Hemagglut inat ion inh ib i t ion assay showing patterns 
for positive and negative results. 
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HCG. Their primary application is to verify normal preg-
nancy in patients reasonably expected to be pregnant. In 
all cases, sources of HCG other than a normal pregnancy 
must be considered in the clinical context. For less spe-
cific tests, the presence of elevated LH must also be ruled 
out. 
HCG, Quantitative (RIA) 
The radioimmunoassay called "beta HCG, quantitative" 
is a sensitive assay specific for both beta subunit and 
intact HCG (Leeco Diagnostics). As with other radioim-
munoassays, radio-iodinated HCG competes with the 
hormone in the patient's serum for binding sites on a 
rabbit antibody specific for the beta subunit of HCG. 
Unknown samples are compared to standards (Fig. 6). 
The antibody used in our Ligand Assay Laboratory is the 
same one used in the qualitative screening test de-
scribed above, but experimental conditions have been 
changed to increase the sensitivity and precision of the 
measurement. LH cross-reacts with this antibody by 
approximately 5% (mlU HCG/mlU LH X 100). Thus, it is 
possible to detect HCG in the serum of men or non-
pregnant women, and usual LH elevations should not 
raise the apparent HCG above the upper limit of normal. 
In our experience, a postmenopausal woman with LH of 
160 m lU /m l had an HCG value of 8 m lU /m l . Quantita-
tive RIA is not designed as a screening test for normal 
pregnancies. Because of the time and expense involved 
and the nature of the clinical applications, HCG beta 
subunit radioimmunoassay is run twice per week in our 
laboratory. 
Considerations for the Choice of HCG Assays 
The cost and turnaround time of pregnancy tests vary 
inversely with their sensitivity. Thus, in ordering a preg-
nancy test, the practitioner must ask, " H o w much time 
and money should I spend for the information?" 
Routine identification of pregnancy can usually wait 
unti l two weeks after the missed period when a tube test 
<-HCG ^ N^HCG 
-^-HCG-izsi^ , 
Bovine corpus HCG-125I 
luteum 1 Spin 
[count 
HCG _ ^ HCG-anti-HCG 
- HCG *HCG-anti HCG 
1 add anti IgG 
1 spin, count 
Fig. 5 
Radioreceptor assay for HCG. Patient hormone (<-HCC) competes 
wi th i " i . |abe led-HCG ( • H C C ) for receptor sites. 
Fig. 6 
Radioimmunoassay for HCG using a second antibody separation. 
and conf i rming examination are sufficient. If referral for 
pregnancy termination is a consideration, immediate 
identif ication of a pregnancy provides better informa-
tion about the decision to have an abort ion at a t ime 
when complications are low. Here, a serum pregnancy 
test with increased sensitivity is appropriate. Anxiety 
about exposure to infection or toxins is another justifica-
tion for early serum testing. 
Economic, medico-legal, and clinical considerations 
determine whether routine useof sensitiveserum preg-
nancy tests is appropriate. For example, for patients who 
are to be exposed to radiation, anesthetic gases, surgery, 
or who are to receive teratogenic medications or undergo 
radiological or surgical procedures, the early identifica-
t ion of pregnancy is important. The radiologist and sur-
geon must recognize that no pregnancy test presently 
available wil l detect pregnancy between the t ime of 
ferti l ization and implantation. Shortly after implanta-
t ion, the quantitative beta subunit assay wil l become 
positive. About four days later, the pregnancy screening 
test used in our laboratory wil l identify pregnancy. 
Because of the possibility of an ectopic implantation, 
identif ication of pregnancy is desirable in a woman who 
is experiencing menstrual irregularity and lower abdom-
inal pain. All viable ectopic pregnancies secrete HCG. A 
negative serum test of sufficient sensitivity (30 mlU/ml) 
excludes the possibility of tubal pregnancy with over 
95% reliabil i ty.Thedistinction between intrauterineand 
ectopic gestation, however, cannot be made on the basis 
of a qualitative HCG assay. The use of ultrasound can 
resolve this diagnostic dilemma by the visualization of 
the gestational sac approximately five weeks after the 
last menstrual period. Moreover, in an intrauterine 
pregnancy with serum HCG above6,500 mlU/ml , thesac 
wil l always be visualized. Therefore, for a patient with 
lower abdominal pain, an HCG level greater than 6,500 
m l U / m l , and no gestational sac visible on ultrasound, 
the l ikel ihood of ectopic gestation is high. When the 
HCG level is below 6,500 m l U / m l , the clinician must rely 
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on other means to establish the diagnosis of ectopic 
pregnancy. 
In the case of threatened miscarriage (bleeding and/or 
cramping), HCG levels may help establish the prognosis. 
If the date of conception is known, a single determina-
t ion predicts miscarriage with over 80% accuracy when 
the value is clearly below the normal range. Accurate 
determination o f the date of conception is not necessary 
if serial HCG values are obtained. As noted above, HCG 
normally rises with a dou bling t ime of 1.7-2.0 days during 
the firstsix weeks of pregnancy. If serial HCG determina-
tions show a doubl ing t ime slower than two days, the 
l ikel ihood of miscarriage is high. The use of serial HCG 
determinations to fol low early pregnancy does not 
supply information that would allow a clinician to inter-
vene significantly. 
HCG may serve as a marker for ovarian germ cell tumors. 
In addit ion, very large amounts of HCG are secreted by 
hydatidiform mole, a non-malignant neoplasm of the 
placenta. In approximately 7% of cases, hydatidiform 
mole progresses to trophoblastic choriocarcinoma. When 
HCG levels fail to decline appropriately after a mole has 
been evaluated, the patient should be treated by che-
motherapy for gestational trophoblastic disease. Con-
t inuing HCG measurements are often made to evaluate 
the effectiveness and adequacy of treatment. 
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